文献速递白血病造血干细胞移植与细胞治疗

前瞻性分析确定急性白血病患者接受异基因造血细胞移植的障碍

Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
PubMed 文献 · Am J Hematol · 2023-09-09

这项前瞻性观察研究在2016年4月至2021年4月纳入307例新诊断或复发/难治急性白血病成人患者,在诱导/再诱导早期进行移植评估并给出建议。85%(n=259)被推荐移植,其中66%(n=170)实际接受移植;最常见未移植原因为持续/复发疾病(70%),其次为早期患者死亡(10%)。

要点

  • 307例急性白血病患者中85%(n=259)被推荐异基因造血细胞移植,其中66%(n=170)实际接受移植。
  • 89例被推荐但未移植的患者中,未移植最常见原因为持续/复发疾病(70%),其次为早期患者死亡(10%)。
  • 供者来源包括54% HLA相合无关供者、20% HLA相合同胞供者、15%脐带血、8% HLA不合无关供者和4% HLA单倍体供者。

核心结论

  • 本前瞻性研究报告较高的异基因造血细胞移植率,可能归因于早期移植转诊和评估。
  • 异基因造血细胞移植的主要障碍是疾病控制,其次是早期患者死亡。
  • 随着HLA不合移植来源日益可及,供者缺乏不再构成移植障碍。
  • 作者认为,为未达到缓解的患者进一步开发新的移植策略以及改进诱导方案,可能提高异基因造血细胞移植的利用率。

研究设计与样本

  • 前瞻性观察性研究,2016年4月至2021年4月纳入307例新诊断或复发/难治急性白血病成人患者,在诱导/再诱导治疗时入组。
  • 在诱导/再诱导早期进行初始移植评估并给出异基因造血细胞移植建议。

主要发现

  • 307例入组患者中,85%(n=259)被推荐异基因造血细胞移植,其中66%(n=170)接受了移植。
  • 供者来源包括54% HLA相合无关供者、20% HLA相合同胞供者,以及HLA不合移植来源中15%脐带血单位、8% HLA不合无关供者和4% HLA单倍体供者。
  • 89例最初被推荐但未移植的患者中,移植取消最常见原因为持续/复发疾病(70%),其次为早期患者死亡(10%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate and eligible for HCT did not subsequently undergo transplant. Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy. Initial transplantation workup and allo-HCT recommendations were made during the early phase of induction/reinduction. Of the 307 enrolled patients, allo-HCT was recommended to 85% (n = 259), of whom 66% (n = 170) underwent transplant. Donor sources comprised 54% human leukocyte antigen (HLA)-matched unrelated donors, 20% HLA-matched sibling donors and HLA-mismatched graft sources with 15% umbilical cord blood units, 8% HLA-mismatched unrelated donors, and 4% HLA-haploidentical donors. The most common reason for transplant disqualification in the 89 patients in whom it was initially recommended was persistent/relapsed disease (70%), followed by early patient death (10%). In this prospective study, we report a high allo-HCT rate, which may be due to early transplant referral and workup. The main allo-HCT barrier was disease control, followed by early patient death. With the increasing availability of HLA-mismatched graft sources, the lack of donor availability was not a transplant barrier. Further development of novel transplant strategies for patients not achieving remission and improvements in induction regimens could result in increased allo-HCT utilization.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Nath K, Lee J, Elko TA, et al. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia. Am J Hematol. 2023. PMID: 37688521. doi:10.1002/ajh.27084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。